A Phase 2 interventional study of Vamorolone 0.25 mg/day/day and Vamorolone 0.75 mg/day/day in Duchenne Muscular Dystrophy, sponsored by ReveraGen BioPharma, Inc.. Completed at 12 sites in 6 countries. Open to male participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2019-07-23.
Sponsored by ReveraGen BioPharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 58th largest by enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2016, is one of 57 in phase 2, and was the 100th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 7 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 90 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 15 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 171 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 232 have an industry lead sponsor. The 10 most frequent:
ReveraGen BioPharma, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
ReveraGen BioPharma, Inc. has 5 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purposes of this study are to see if it is safe to use a new medication called vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see if vamorolone works for the treatment for DMD, and to see how any potential side effects compare to those seen in boys using steroids.
This study will evaluate if it is safe to use a new medication called vamorolone for more than two weeks in children with DMD, if boys with DMD who take the study medication have improved muscle function compared to boys with DMD in other studies who did not take any type of steroid, and to see if boys with DMD who take the study medication gain less weight compared to boys with DMD in a prior study who took another type of steroid called prednisone. Enrolled participants will take the study medication for 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Participants may be re-evaluated if ineligible due to a transient condition which would prevent the subject from participating
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Drug: Vamorolone 0.25 mg/day/day
Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Drug: Vamorolone 0.75 mg/day/day
Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Drug: Vamorolone 2.0 mg/day/day
Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Drug: Vamorolone 6.0 mg/day/day
Drug page: Vamorolone
Oral administration of 0.25 mg/kg/day daily for 24 weeks.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 0.75 mg/kg/day daily for 24 weeks.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 2.0 mg/kg/day daily for 24 weeks.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 6.0 mg/kg/day daily for 24 weeks.
Also known as: VBP15
Number of Participants With Adverse Events as Assessed by CTCAE Version 4.03
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug; To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- week Treatment Period, in boys ages 4-7 years with DMD.
Time frame: 24 weeks
Total Number of Adverse Events as Assessed by CTCAE Version 4.03
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug; To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- week Treatment Period, in boys ages 4-7 years with DMD.
Time frame: 24 weeks
Muscle Function Measured by Time to Stand Test (TTSTAND)- Velocity
To compare the efficacy, as measured by the Time to Stand Test (TTSTAND), of vamorolone administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. untreated DMD historical controls in boys ages 4-7 years with DMD
Time frame: 002 Baseline, 003 Baseline, 003 Week 12, Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
BMI Z-score
Summary of BMI Z-score of Safety Population. Please note 0 is the mean. A negative result indicates a response that is many standard deviations below the mean, and a positive result indicates a response that is many standard deviations above the mean. In this case, the closer the group mean BMI Z-score is to 0 is more favorable.
Time frame: 002 Baseline, 003 Week 12, Week 24
Serum Pharmacodynamics Biomarkers Measured by Levels of HbA1c
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
Time frame: 002 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29
Serum Pharmacodynamics Biomarkers Measured by Levels of ACTH
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
Time frame: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
Serum Pharmacodynamics Biomarkers Measured by Levels of Fasting Glucose
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
Time frame: 002 Baseline, 003 Week 12, 003 Week 24
Serum Pharmacodynamics Biomarkers Measured by Levels of Fasting Insulin
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
Time frame: 002 Baseline, 003 Week 12, 003 Week 24
Serum Pharmacodynamics Biomarkers Measured by Levels of Osteocalcin
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
Time frame: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
Serum Pharmacodynamics Biomarkers Measured by Levels of P1NP
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
Time frame: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
Serum Pharmacodynamics Biomarkers Measured by Levels of CTX
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
Time frame: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
Muscle Strength, Mobility, and Functional Exercise Capacity as Measured by Time to Climb Test (TTCLIMB)- Velocity
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by Time to Climb Test (TTCLIMB) in boys ages 4-7 years with DMD.
Time frame: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
Muscle Strength, Mobility, and Functional Exercise Capacity as Measured by Time to Run/Walk 10 Meters Test (TTRW)- Velocity
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by Time to Run/Walk Test (TTRW) in boys ages 4-7 years with DMD.
Time frame: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
Muscle Strength, Mobility, and Functional Exercise Capacity as Measured by North Star Ambulatory Assessment (NSAA)
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by North Star Ambulatory Assessment (NSAA) in boys ages 4-7 years with DMD. \*\*\*Total NSAA score is being reported. The score can range from 0 to 32. Higher scores (approaching 32) indicate a better outcome assessing functional mobility.
Time frame: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
Muscle Strength, Mobility, and Functional Exercise Capacity vs. Historical Controls as Measured by 6-minute Walk Test (6MWT) Meters
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by 6-minute Walk Test (6MWT) in boys ages 4-7 years with DMD.
Time frame: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Milestone | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Started | 12 | 0 | 0 | 0 |
| Completed | 12 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Started | 0 | 12 | 0 | 0 |
| Completed | 0 | 12 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Started | 0 | 0 | 12 | 0 |
| Completed | 0 | 0 | 12 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 12 |
| Completed | 0 | 0 | 0 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug; To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- week Treatment Period, in boys ages 4-7 years with DMD.
| participants | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Subjects with Any TEAE | 10 | 10 | 11 | 11 |
| Subjects with Any Drug Related TEAE | 1 | 2 | 4 | 5 |
| Subjects with Any CTCAE Grade 3 or Higher TEAE | 0 | 0 | 0 | 2 |
| Discontinuation of Study Drug due to TEAE | 0 | 0 | 0 | 0 |
| Subjects with Any Serious TEAE | 0 | 1 | 0 | 2 |
| Death | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug; To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- week Treatment Period, in boys ages 4-7 years with DMD.
| Events | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Total Number of AEs | 48 | 44 | 54 | 73 |
| Total Number of TEAEs | 48 | 44 | 54 | 72 |
To compare the efficacy, as measured by the Time to Stand Test (TTSTAND), of vamorolone administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. untreated DMD historical controls in boys ages 4-7 years with DMD
| Rises/Second | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 0.18 ± 0.065 | 0.24 ± 0.090 | 0.22 ± 0.082 | 0.19 ± 0.056 |
| 003 Baseline | 0.15 ± 0.045 | 0.22 ± 0.077 | 0.24 ± 0.078 | 0.22 ± 0.070 |
| 003 Week 12 | 0.18 ± 0.072 | 0.23 ± 0.102 | 0.24 ± 0.089 | 0.22 ± 0.075 |
| 003 Week 12 Change from 002 Baseline | -0.01 ± 0.061 | 0.00 ± 0.054 | 0.02 ± 0.066 | 0.02 ± 0.034 |
| 003 Week 24 | 0.18 ± 0.081 | 0.24 ± 0.114 | 0.26 ± 0.108 | 0.24 ± 0.086 |
| 003 Week 24 Change from 002 Baseline | -0.01 ± 0.066 | 0.00 ± 0.062 | 0.05 ± 0.061 | 0.04 ± 0.045 |
Summary of BMI Z-score of Safety Population. Please note 0 is the mean. A negative result indicates a response that is many standard deviations below the mean, and a positive result indicates a response that is many standard deviations above the mean. In this case, the closer the group mean BMI Z-score is to 0 is more favorable.
| z score | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 1.165 ± 0.6219 | 0.703 ± 1.0738 | 1.200 ± 0.5325 | 0.695 ± 0.7189 |
| 003 Week 12 | 1.103 ± 0.6457 | 0.494 ± 1.0680 | 1.261 ± 0.3981 | 1.011 ± 0.7034 |
| 003 Week 12 Change from 002 Baseline | -0.062 ± 0.2438 | -0.209 ± 0.4078 | 0.062 ± 0.3886 | 0.174 ± 0.5826 |
| 003 Week 24 | 1.004 ± 0.6381 | 0.493 ± 1.1696 | 1.242 ± 0.4596 | 1.330 ± 0.5857 |
| 003 Week 24 Change from 002 Baseline | -0.161 ± 0.3234 | -0.210 ± 0.3629 | 0.043 ± 0.3849 | 0.493 ± 0.6363 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| % of HbA1c | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 5.18 ± 0.260 | 5.22 ± 0.244 | 5.19 ± 0.124 | 5.23 ± 0.231 |
| 003 Week 8 | 5.18 ± 0.226 | 5.33 ± 0.250 | 5.28 ± 0.204 | 5.25 ± 0.216 |
| 003 Week 8 Change from 002 Baseline | 0.00 ± 0.128 | 0.12 ± 0.153 | 0.09 ± 0.198 | 0.00 ± 0.100 |
| 003 Week 16 | 5.26 ± 0.239 | 5.35 ± 0.238 | 5.26 ± 0.156 | 5.31 ± 0.270 |
| 003 Week 16 Change from 002 Baseline | 0.08 ± 0.204 | 0.14 ± 0.225 | 0.07 ± 0.130 | 0.05 ± 0.113 |
| 003 Week 24 | 5.15 ± 0.302 | 5.22 ± 0.221 | 5.13 ± 0.160 | 5.24 ± 0.254 |
| 003 Week 24 Change from 002 Baseline | -0.10 ± 0.220 | 0.00 ± 0.186 | -0.07 ± 0.130 | -0.02 ± 0.154 |
| 003 Week 26-29 | 5.07 ± 0.208 | — | — | — |
| 003 Week 26-29 Change from 002 Baseline | -0.07 ± 0.208 | — | — | — |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| % change | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 003 Week 8 % Change from 002 Baseline | 0.06 ± 2.470 | 2.28 ± 3.008 | 1.79 ± 3.864 | 0.02 ± 1.927 |
| 003 Week 16 % Change from 002 Baseline | 1.70 ± 3.989 | 2.72 ± 4.457 | 1.30 ± 2.505 | 1.03 ± 2.14 |
| 003 Week 24 % Change from 002 Baseline | -1.89 ± 4.801 | 0.08 ± 3.629 | -1.27 ± 2.525 | -0.33 ± 2.895 |
| 003 Week 26-29 % Change from 002 Baseline | -1.25 ± 3.942 | — | — | — |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| pg/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 18.3 ± 2.96 | 18.0 ± 6.88 | 21.1 ± 6.13 | 19.3 ± 8.67 |
| 003 Baseline | 15.9 ± 4.52 | 18.6 ± 4.56 | 18.2 ± 5.29 | 18.4 ± 9.73 |
| 003 Week 8 | 13.0 ± 6.25 | 7.1 ± 5.84 | 7.8 ± 4.42 | 6.5 ± 5.23 |
| 003 Week 8 Change from 002 Baseline | -5.3 ± 6.92 | -10.5 ± 9.32 | -13.3 ± 7.33 | -13.5 ± 7.84 |
| 003 Week 16 | 12.2 ± 4.93 | 9.0 ± 5.86 | 9.0 ± 14.18 | 9.0 ± 4.49 |
| 003 Week 16 Change from 002 Baseline | -6.2 ± 6.34 | -9.1 ± 9.89 | -12.0 ± 15.42 | -12.2 ± 8.16 |
| 003 Week 24 | 19.8 ± 6.32 | 14.0 ± 3.88 | 15.7 ± 9.63 | 11.3 ± 7.52 |
| 003 Week 24 Change from 002 Baseline | 0.6 ± 6.63 | -4.0 ± 5.48 | -5.4 ± 11.09 | -6.3 ± 7.78 |
| 003 Week 26-29 | 9.5 ± 7.26 | — | — | — |
| 003 Week 26-29 Change from 002 Baseline | -7.8 ± 4.19 | — | — | — |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| mg/dL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 87.5 ± 9.44 | 88.9 ± 18.71 | 89.3 ± 7.91 | 92.3 ± 8.19 |
| 003 Week 12 | 81.5 ± 5.61 | 81.7 ± 4.35 | 84.3 ± 8.13 | 86.5 ± 5.57 |
| 003 Week 12 Change from 002 Baseline | -6.8 ± 8.29 | -7.6 ± 19.22 | -5.1 ± 9.01 | -5.2 ± 9.21 |
| 003 Week 24 | 80.8 ± 6.56 | 80.8 ± 4.08 | 81.3 ± 7.94 | 84.6 ± 6.53 |
| 003 Week 24 Change from 002 Baseline | -6.3 ± 11.97 | -9.0 ± 20.87 | -8.1 ± 10.28 | -7.8 ± 9.44 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| uIU/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 5.54 ± 3.651 | 3.09 ± 2.033 | 3.40 ± 1.548 | 3.96 ± 2.027 |
| 003 Week 12 | 4.17 ± 3.167 | 2.97 ± 1.669 | 3.89 ± 2.189 | 6.97 ± 3.526 |
| 003 Week 12 Change from 002 Baseline | -1.13 ± 3.822 | -0.14 ± 1.756 | 0.49 ± 2.592 | 2.97 ± 2.277 |
| 003 Week 24 | 4.23 ± 2.560 | 3.12 ± 1.788 | 4.82 ± 3.393 | 7.21 ± 2.374 |
| 003 Week 24 Change from 002 Baseline | -1.67 ± 4.478 | 0.34 ± 2.898 | 1.36 ± 3.262 | 3.26 ± 2.862 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| ng/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 37.94 ± 11.622 | 35.66 ± 6.800 | 41.17 ± 5.617 | 44.36 ± 5.979 |
| 003 Baseline | 39.20 ± 14.136 | 41.84 ± 8.552 | 47.91 ± 6.648 | 42.81 ± 10.851 |
| 003 Week 8 | 36.21 ± 10.374 | 41.78 ± 13.856 | 44.45 ± 7.439 | 41.55 ± 5.446 |
| 003 Week 8 Change from 002 Baseline | -1.60 ± 8.849 | 6.13 ± 10.440 | 3.28 ± 8.325 | -2.01 ± 8.898 |
| 003 Week 16 | 39.01 ± 9.620 | 42.23 ± 9.393 | 44.60 ± 9.534 | 39.39 ± 6.972 |
| 003 Week 16 Change from 002 Baseline | 1.07 ± 9.916 | 6.57 ± 6.709 | 3.43 ± 10.718 | -4.17 ± 8.494 |
| 003 Week 24 | 38.80 ± 6.292 | 51.41 ± 11.265 | 51.98 ± 9.372 | 49.08 ± 7.771 |
| 003 Week 24 Change from 002 Baseline | -1.34 ± 11.289 | 15.75 ± 10.211 | 10.81 ± 7.542 | 5.29 ± 7.858 |
| 003 Week 26-29 | 40.10 ± 18.729 | — | — | — |
| 003 Week 26-29 Change from 002 Baseline | -1.23 ± 17.943 | — | — | — |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| ng/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 555.8 ± 184.72 | 480.7 ± 118.20 | 508.2 ± 94.36 | 511.5 ± 106.50 |
| 003 Baseline | 573.9 ± 251.02 | 489.3 ± 121.66 | 492.0 ± 81.92 | 566.3 ± 149.32 |
| 003 Week 8 | 511.6 ± 190.94 | 459.8 ± 101.93 | 485.2 ± 105.12 | 402.7 ± 70.46 |
| 003 Week 8 Change from 002 Baseline | -20.3 ± 120.32 | -22.9 ± 128.79 | -23.0 ± 96.84 | -105.6 ± 121.07 |
| 003 Week 16 | 481.9 ± 159.93 | 431.8 ± 81.25 | 455.7 ± 99.50 | 488.5 ± 130.11 |
| 003 Week 16 Change from 002 Baseline | -73.8 ± 109.31 | -42.4 ± 109.07 | -52.5 ± 104.05 | -19.8 ± 130.12 |
| 003 Week 24 | 457.1 ± 129.21 | 471.1 ± 121.10 | 565.5 ± 158.89 | 526.2 ± 130.18 |
| 003 Week 24 Change from 002 Baseline | -30.8 ± 113.64 | 2.1 ± 165.16 | 57.3 ± 150.36 | 8.7 ± 88.95 |
| 003 Week 26-29 | 619.0 ± 379.07 | — | — | — |
| 003 Week 26-29 Change from 002 Baseline | -152.0 ± 331.46 | — | — | — |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein.
| pg/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 871.0 ± 160.85 | 935.8 ± 286.50 | 936.8 ± 256.25 | 889.3 ± 186.68 |
| 003 Baseline | 915.9 ± 263.13 | 964.4 ± 319.26 | 949.8 ± 303.76 | 989.2 ± 216.29 |
| 003 Week 8 | 897.1 ± 365.45 | 933.3 ± 330.20 | 928.3 ± 333.11 | 825.5 ± 164.36 |
| 003 Week 8 Change from 002 Baseline | 26.1 ± 368.76 | -31.6 ± 236.34 | -8.5 ± 248.82 | -59.6 ± 259.08 |
| 003 Week 16 | 885.4 ± 261.53 | 912.8 ± 305.08 | 939.8 ± 157.17 | 953.7 ± 199.53 |
| 003 Week 16 Change from 002 Baseline | -2.6 ± 304.50 | -46.3 ± 321.06 | 3.0 ± 244.71 | 102.3 ± 230.44 |
| 003 Week 24 | 1109.3 ± 287.92 | 1235.6 ± 295.79 | 1248.7 ± 308.90 | 1237.0 ± 277.20 |
| 003 Week 24 Change from 002 Baseline | 212.3 ± 318.86 | 295.6 ± 357.93 | 346.5 ± 327.16 | 321.4 ± 264.65 |
| 003 Week 26-29 | 1059.3 ± 536.26 | — | — | — |
| 003 Week 26-29 Change from 002 Baseline | 569.5 ± 28.99 | — | — | — |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by Time to Climb Test (TTCLIMB) in boys ages 4-7 years with DMD.
| tasks/ second | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 0.20 ± 0.054 | 0.29 ± 0.147 | 0.29 ± 0.164 | 0.24 ± 0.086 |
| 003 Baseline | 0.20 ± 0.065 | 0.29 ± 0.168 | 0.31 ± 0.144 | 0.25 ± 0.082 |
| 003 Week 12 | 0.21 ± 0.064 | 0.34 ± 0.238 | 0.31 ± 0.157 | 0.26 ± 0.095 |
| 003 Week 12 Change from 002 Baseline | 0.01 ± 0.044 | 0.05 ± 0.115 | 0.02 ± 0.107 | 0.02 ± 0.051 |
| 003 Week 24 | 0.20 ± 0.071 | 0.30 ± 0.166 | 0.34 ± 0.148 | 0.29 ± 0.097 |
| 003 Week 24 Change from 002 Baseline | 0.00 ± 0.076 | 0.01 ± 0.066 | 0.04 ± 0.090 | 0.05 ± 0.061 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by Time to Run/Walk Test (TTRW) in boys ages 4-7 years with DMD.
| meters/ second | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 1.60 ± 0.312 | 1.77 ± 0.367 | 1.84 ± 0.347 | 1.64 ± 0.279 |
| 003 Baseline | 1.57 ± 0.371 | 1.78 ± 0.414 | 1.86 ± 0.418 | 1.72 ± 0.295 |
| 003 Week 12 | 1.54 ± 0.306 | 1.77 ± 0.550 | 1.97 ± 0.503 | 1.88 ± 0.341 |
| 003 Week 12 Change from 002 Baseline | -0.06 ± 0.261 | 0.00 ± 0.307 | 0.13 ± 0.316 | 0.26 ± 0.297 |
| 003 Week 24 | 1.55 ± 0.384 | 1.84 ± 0.486 | 1.90 ± 0.321 | 1.89 ± 0.378 |
| 003 Week 24 Change from 002 Baseline | -0.05 ± 0.311 | 0.06 ± 0.210 | 0.06 ± 0.210 | 0.27 ± 0.254 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by North Star Ambulatory Assessment (NSAA) in boys ages 4-7 years with DMD. \*\*\*Total NSAA score is being reported. The score can range from 0 to 32. Higher scores (approaching 32) indicate a better outcome assessing functional mobility.
| scores on a scale | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 19.0 ± 5.13 | 20.5 ± 5.58 | 20.0 ± 4.95 | 19.7 ± 4.94 |
| 003 Baseline | 20.1 ± 7.30 | 20.8 ± 5.66 | 21.7 ± 3.87 | 20.4 ± 4.01 |
| 003 Week 12 | 19.3 ± 5.60 | 21.2 ± 6.45 | 21.0 ± 5.13 | 20.4 ± 5.41 |
| 003 Week 12 Change from 002 Baseline | 0.3 ± 2.06 | 0.7 ± 2.71 | 1.0 ± 2.56 | 0.5 ± 2.38 |
| 003 Week 24 | 19.8 ± 7.09 | 21.6 ± 7.23 | 22.3 ± 3.80 | 22.3 ± 5.76 |
| 003 Week 24 Change from 002 Baseline | 0.8 ± 2.83 | 1.1 ± 2.94 | 2.3 ± 1.78 | 2.5 ± 2.62 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by 6-minute Walk Test (6MWT) in boys ages 4-7 years with DMD.
| Meters | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| 002 Baseline | 316.2 ± 59.47 | 331.5 ± 52.76 | 353.9 ± 65.40 | 336.8 ± 63.18 |
| 003 Baseline | 294.3 ± 60.62 | 332.2 ± 56.83 | 341.1 ± 49.42 | 335.1 ± 80.13 |
| 003 Week 12 | 312.9 ± 60.93 | 358.7 ± 71.47 | 393.7 ± 59.72 | 369.9 ± 69.47 |
| 003 Week 12 Change from 002 Baseline | 6.0 ± 28.81 | 20.8 ± 38.09 | 39.8 ± 35.61 | 27.6 ± 42.00 |
| 003 Week 24 | 306.2 ± 68.08 | 350.4 ± 64.23 | 383.1 ± 63.38 | 372.6 ± 69.12 |
| 003 Week 24 Change from 002 Baseline | -11.6 ± 29.45 | 18.9 ± 41.08 | 29.2 ± 35.91 | 43.9 ± 43.72 |
Collected over Adverse events, including Serious Adverse Events (SAEs), and concomitant medications will be assessed at each study visit and recorded throughout the 24 week treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level Group 1 | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Dose Level Group 2 | 0/12 (0%) | 1/12 (8.3%) | 10/12 (83.3%) |
| Dose Level Group 3 | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Dose Level Group 4 | 0/12 (0%) | 2/12 (16.7%) | 11/12 (91.7%) |
| Event | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/12 | 1/12 | 0/12 | 0/12 |
| DehydrationMetabolism and nutrition disorders | 0/12 | 0/12 | 0/12 | 1/12 |
| Testicular TorsionReproductive system and breast disorders | 0/12 | 0/12 | 0/12 | 1/12 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 0/12 | 1/12 |
| Event | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/12 | 7/12 | 5/12 | 3/12 |
| Viral upper respiratory tract infectionInfections and infestations | 4/12 | 4/12 | 7/12 | 5/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/12 | 4/12 | 1/12 | 3/12 |
| VomitingGastrointestinal disorders | 1/12 | 1/12 | 3/12 | 2/12 |
| InfluenzaInfections and infestations | 1/12 | 0/12 | 0/12 | 3/12 |
| Abdominal pain upperGastrointestinal disorders | 0/12 | 0/12 | 1/12 | 2/12 |
| ConstipationGastrointestinal disorders | 1/12 | 0/12 | 1/12 | 2/12 |
| DiarrhoeaGastrointestinal disorders | 2/12 | 0/12 | 2/12 | 1/12 |
| ConjunctivitisInfections and infestations | 1/12 | 0/12 | 2/12 | 1/12 |
| Eye infectionInfections and infestations | 2/12 | 0/12 | 0/12 | 0/12 |
All subjects who receive at least one dose of vamorolone study medication in the extension study will be included in the Safety Population. The Safety Population is the primary analysis population for safety assessments.
| Age, Customized(years) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Age | 5.2 ± 1.03 | 4.8 ± 0.83 | 4.7 ± 0.89 | 4.8 ± 0.75 | 4.9 ± 0.87 |
| Sex/Gender, Customized(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Male | 12 | 12 | 12 | 12 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 3 | 4 |
| Not Hispanic or Latino | 12 | 11 | 12 | 9 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 |
| White | 11 | 10 | 12 | 12 | 45 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Canada | 3 | 0 | 2 | 2 | 7 |
| Sweden | 0 | 4 | 0 | 0 | 4 |
| United States | 9 | 3 | 2 | 6 | 20 |
| United Kingdom | 0 | 0 | 4 | 2 | 6 |
| Israel | 0 | 3 | 2 | 0 | 5 |
| Australia | 0 | 2 | 2 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Apr 2018, 20 months.
Results were first posted in Jul 2019, 1 year 2 months after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 20 months is below that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vamorolone
Muscular Dystrophy, Duchenne →
ReveraGen BioPharma, Inc.